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Hearing impairment (HI) affects 1 in 650 newborns, which makes it the most common congenital sensory impair-
ment. Despite extraordinary genetic heterogeneity, mutations in one gene, GJB2, which encodes the connexin 26
protein and is involved in inner ear homeostasis, are found in up to 50% of patients with autosomal recessive
nonsyndromic hearing loss. Because of the high frequency of GJB2 mutations, mutation analysis of this gene is
widely available as a diagnostic test. In this study, we assessed the association between genotype and degree of
hearing loss in persons with HI and biallelic GJB2 mutations. We performed cross-sectional analyses of GJB2
genotype and audiometric data from 1,531 persons, from 16 different countries, with autosomal recessive, mild-
to-profound nonsyndromic HI. The median age of all participants was 8 years; 90% of persons were within the
age range of 0–26 years. Of the 83 different mutations identiﬁed, 47 were classiﬁed as nontruncating, and 36 as
truncating. A total of 153 different genotypes were found, of which 56 were homozygous truncating (T/T), 30
were homozygous nontruncating (NT/NT), and 67 were compound heterozygous truncating/nontruncating (T/
NT). The degree of HI associated with biallelic truncating mutations was signiﬁcantly more severe than the HI
associated with biallelic nontruncating mutations ( ). The HI of 48 different genotypes was less severeP ! .0001
than that of 35delG homozygotes. Several common mutations (M34T, V37I, and L90P) were associated with mild-
to-moderate HI (median 25–40 dB). Two genotypes—35delG/R143W (median 105 dB) and 35delG/dela(GJB6-
D13S1830) (median 108 dB)—had signiﬁcantly more-severe HI than that of 35delG homozygotes.
Introduction
Hearing impairment (HI) affects 1 in 650 newborns (Mehl
and Thomson 2002), which makes it the most frequent
congenital sensory impairment. In most of these cases,
the inheritance pattern is autosomal recessive (80%), al-
though autosomal dominant (17%), X-linked (2%–3%),
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and mitochondrial (!1%) inheritance also occur. In 30%
of cases, additional physical ﬁndings lead to the diag-
nosis of 1 of 1400 syndromes in which hearing loss can
be a clinical component. In the remaining 70% of cases,
nonsyndromic HI is diagnosed (Morton 1991).
Nonsyndromic HI is extraordinarily heterogeneous—
∼100 localizations have been reported across the genome
as sites of genes causally related to nonsyndromic HI,
and 37 different genes encoding proteins with a wide
variety of functions have been identiﬁed. Despite this
degree of heterogeneity, variants of one gene, GJB2
(MIM 121011), account for up to 50% of cases of
autosomal recessive nonsyndromic HI in many world
populations, which makes GJB2 the gene most fre-
quently associated with this condition (Kenneson et al.
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2002). A few speciﬁc mutations in GJB2 also have been
described in families with autosomal dominant HI, with
and without skin manifestations, although their preva-
lence is low (Denoyelle et al. 1998).
GJB2 encodes the connexin 26 (CX26) protein, a
member of the connexin family of highly related gap-
junction proteins. Connexins oligomerize to form hexa-
meric hemichannels called “connexons,” which are pres-
ent in the plasma membrane, where they can bind with
connexons from adjacent cells to form functional gap
junctions (Bruzzone et al. 1996). These junctional chan-
nels are permeable to ions and small metabolites with
molecular masses up to 1,200 Da (Harris and Bevans
2001). They can be composed of one (homomeric) or
more (heteromeric) connexins, thereby modifying selec-
tive permeability of gap junctions (Stauffer 1995).
Expression of GJB2 has been documented in a variety
of cells and tissues. In the cochlea, CX26-containing gap
junctions are proposed to maintain K homeostasis by
ferrying K away from the hair cells during auditory
transduction (Kikuchi et al. 1995). Recently, it has been
shown that the intercellular transduction of the second
messenger inositol triphosphate (IP3) is also essential for
the perception of sound (Beltramello et al. 2005). In the
epidermis, CX26-containing gap junctions play a role
in coordinated keratinocyte growth and differentiation
(Choudhry et al. 1997), which explains the skin abnor-
malities associated with autosomal dominant HI in per-
sons who segregate a few mutations in GJB2 that affect
the ﬁrst extracellular domain of CX26 and exert a dom-
inant negative effect by impairing interconnexon dock-
ing (Maestrini et al. 1999; Heathcote et al. 2000; Al-
varez et al. 2003).
Many HI-causing mutations of GJB2 have been re-
ported (Connexin-Deafness Home Page), some of which
are very common and others of which are extremely
rare. The mutation spectrum diverges substantially
among populations, as reﬂected by speciﬁc ethnic biases
for common mutations like 35delG among whites (car-
rier rate of 2%–4%) (Zelante et al. 1997; Estivill et al.
1998; Green et al. 1999), 235delC in the Japanese (car-
rier rate of 1%–2%) (Abe et al. 2000; Kudo et al. 2000),
167delT in the Ashkenazi Jewish population (carrier
rate of 7.5%) (Morell et al. 1998), and V37I in Taiwan
(carrier rate of 11.6%) (Hwa et al. 2003). Despite this
variability, the combined frequency of all GJB2 muta-
tions is sufﬁciently high in most populations to make
mutation analysis of this gene a clinically useful, and
therefore widely available, genetic test.
TheHI in personswith biallelicGJB2mutations ranges
from mild to profound and is most commonly nonpro-
gressive (Denoyelle et al. 1999;Murgia et al. 1999). Gen-
erally, phenotypic variability has been attributed to un-
known modiﬁer genes or environmental factors. Pre-
vious reports have attempted to addressGJB2 genotype-
phenotype correlations, but only a few associations have
been recognized, a limitation reﬂecting the large number
of genotypes and a small number of affected patients
in most series.
In the largest study reported earlier, we investigated
possible genotype-phenotype correlations in a data set
of 277 unrelated hearing impaired persons with biallelic
GJB2 mutations and showed that persons homozy-
gous for the 35delG mutation have signiﬁcantly more-
severe HI than do 35delG/non-35delG compound het-
erozygotes. Persons with two non-35delG mutations
have even less severe HI. Because of data set size, we
were able to develop only a few speciﬁc genotype-phe-
notype correlations (Cryns et al. 2004). This limitation
prompted us to complete this large multicenter study to
describe more-detailed genotype-phenotype associations
for this frequent form of hereditary HI.
Material and Methods
Patient Recruitment
Persons with congenital HI were sequentially accrued
from otolaryngology departments and genetics units. All
patient information was obtained between 1980 and
2003. Individuals with syndromic, unilateral, acquired,
or dominant types of HI were excluded from this study.
The clinical evaluation included a complete history, phys-
ical examination, and audiometry. Information on eth-
nicity was obtained by a combination of self-reporting
and physician assessment. Most Arabs were collected by
the Pediatric Molecular Genetics Unit, Ankara Univer-
sity School of Medicine (Ankara, Turkey), and the De-
partment of Human Genetics and Molecular Medicine,
Tel Aviv University (Tel Aviv). The latter research group
also collected the majority of Ashkenazi Jews. The Af-
rican and Asian participants, as well as someArabs, were
immigrants. Informed consent to allow genetic testing
was obtained from all participants or from the parents
of minors.
We collected audiometric data from 1,718 patients
with biallelic GJB2 mutations, including del(GJB6-
D13S1830). Of those, 187 patients were excluded be-
cause of additional clinical features or because audio-
metric data were incomplete. Of the 187, 79 were per-
sons whose data were collected using auditory-brain-
stem response (ABR) audiometry (ﬁve laboratories),
which does not provide complete frequency-speciﬁc
thresholds. To avoid bias, data from sibships with mul-
tiple affected siblings were reduced to one randomly cho-
sen hearing impaired individual per family. In the ﬁnal
analysis, detailed audiometric data from 1,531 persons
were included in this study. All samples were anony-
mized, to safeguard patient identity and to preclude the
ability to link a given genotype and audiogram to a
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Table 1
Frequencies of Mutations in Study Participants
Mutation No. (%) of Alleles
Nontruncating:
M1V 3 (.10)
T8M 1 (.03)
G12V 2 (.07)
K15T 2 (.07)
I20T 2 (.07)
V27I 10 (.33)
R32C 2 (.07)
R32H 4 (.13)
M34I 1 (.03)
M34T 123 (4.01)
I35S 1 (.03)
V37I 75 (2.45)
A40E 4 (.13)
G45E 1 (.03)
V52L 1 (.03)
V63M 2 (.07)
W77R 15 (.49)
Q80P 2 (.07)
I82M 4 (.13)
V84L 5 (.16)
L90P 57 (1.86)
L90V 1 (.03)
M93I 1 (.03)
V95M 16 (.52)
H100L 1 (.03)
H100P 1 (.03)
H100Y 3 (.10)
S113R 1 (.03)
E114G 4 (.13)
delE120 23 (.75)
R127H 2 (.07)
L132V 1 (.03)
S138N 1 (.03)
S139N 3 (.10)
I140S 1 (.03)
R143Q 1 (.03)
R143W 13 (.42)
E147K 9 (.29)
M151R 1 (.03)
V153I 5 (.16)
D159N 1 (.03)
C174R 1 (.03)
R184P 21 (.74)
R184W 4 (.13)
S199F 1 (.03)
N206S 11 (.36)
T208P 2 (.07)
Truncating:
28delC 1 (.03)
31del14 1 (.03)
31del38 3 (.10)
35insG 4 (.13)
35delG 2,218 (72.44)
51del12insA 5 (.16)
167delT 91 (2.97)
176del16 1 (.03)
235delC 19 (.62)
269delT 1 (.03)
269insT 7 (.23)
(continued)
Table 1 (continued)
Mutation No. (%) of Alleles
284insdupCACGT 1 (.03)
290insA 2 (.07)
299-300delAT 4 (.13)
310del14 52 (1.70)
313insGG 1 (.03)
328delG 1 (.03)
333-334delAA 5 (.16)
355del9 1 (.03)
383ins7 2 (.07)
511-512insAACG 3 (.10)
558dup46 1 (.03)
631delGT 2 (.07)
W24X 47 (1.53)
W44X 1 (.03)
E47X 43 (1.40)
Q57X 9 (.29)
C64X 1 (.03)
Y65X 2 (.07)
W77X 6 (.20)
Q124X 2 (.07)
Y155X 1 (.03)
W172X 2 (.07)
C211X 2 (.07)
del(GJB6)-D13S1830 51 (1.67)
IVS11GrA 23 (.75)
NOTE.—Alleles in bold italics had frequencies11%.
speciﬁc individual. Institutional approval for this study
was obtained from the University of Antwerp.
Audiometric Evaluation
All patients underwent otoscopic examination and au-
diometric testing. In most cases, hearing levels were de-
termined by pure-tone audiometry, whichwas completed
using a diagnostic audiometer in a soundproof room, in
accordance with International Standards Organization
(ISO 8253-1-3) standards. Five centers also reported be-
havioral testing results for 117 patients (7.6%), and one
center reported the use of steady-state evoked potentials
(SSEPs) for 23 patients (1.5%). SSEPs are electrophysio-
logical measures of hearing acuity used extensively in
Australia, Asia, and Canada. Because the auditory re-
sponse is phase locked to changes in a continuous tonal
stimulus, a higher average sound pressure level can be
delivered than is possible with click stimuli; as a result,
SSEPs can provide an estimate of hearing sensitivity in
children who demonstrate no response to ABR testing.
Pure-tone averages (PTAs) in those cases were recorded
as the SSEP best response (always 100–120 dB).
The binaural mean PTA for air conduction at 0.5, 1,
and 2 kHz (PTA0.5,1,2kHz) was used to compare subgroups
of patients. Average thresholds in the range of 21–40
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Figure 1 Relative frequencies of the degree of HI in the three classes of genotypes. The actual number of participants is given in parentheses.
The three classes were biallelic truncating (T/T), compound heterozygous truncating/nontruncating (T/NT), and biallelic nontruncating (NT/
NT). There were signiﬁcant differences among the three classes, with x2 testing ( ). An additional distinction between 35delG and non-P ! .0001
35delG mutations in the T/T and T/NT classes was made, but statistical analysis (x2 test) revealed no signiﬁcance among these subgroups (data
not shown). The number of persons is shown under each subgroup.
dB were deﬁned as “mild HI,” in the range of 41–70
dB as “moderate HI,” in the range of 71–95 dB as “se-
vere HI,” and 195 dB as “profound HI” (Smith et al.
2005).
GJB2 Mutation Analysis
Various methods—including DNA sequencing, SSCP,
denaturing gradient gel electrophoresis, and denaturing
high-performance liquid chromatography—were used for
mutation analysis of GJB2. In some cases, the 35delG
mutation was detected by an allele-speciﬁc PCR or by
restriction-enzyme digestion of the PCR product (Scott
et al. 1998; Storm et al. 1999). The exact nature of all
GJB2 variants was conﬁrmed by DNA sequencing. PCR
was used to detect del(GJB6-D13S1830), as described
by del Castillo et al. (2002). We considered all allele
variants of GJB2 listed as nonsyndromic HI mutations
on the Connexin-Deafness Home Page to be potentially
pathologic. We also included novel allele variants not
yet listed on that Web site, includingM34I, I35S, L132V,
S138N, I140S, M151R, and T208P. For all these mu-
tations, at least 50 controls with normal hearing were
tested, to determine whether we should exclude the mu-
tations because they are common polymorphisms. With
the exception of T208P, which was found in compound
heterozygosity with W24X in two unrelated persons,
these variants were found only once in compound het-
erozygosity with other GJB2 mutations (table 1). Vari-
ants of debatable pathogenicity, like M34T and V37I,
were also included.
Identiﬁed allele variants were classiﬁed as truncating
or nontruncating mutations. The group of truncating
mutations contained nonsense mutations and deletions,
insertions, and duplications that introduced a shift in
reading frame. The splice-site mutation (IVS11GrA)
and one large deletion, del(GJB6-D13S1830), were also
classiﬁed as truncating, on the basis of published data
(del Castillo et al. 2002; Shahin et al. 2002). The group
of nontruncating mutations contained amino acid sub-
stitutions and one inframe deletion. Although a trans-
lated protein can be made in the presence of these mu-
tations, for some amino acid substitutions, it is possible
that functional activity is lost.
Statistical Analysis
PTA0.5,1,2kHz was used to compare subgroups of pa-
tients.Major genotype-based pairwise comparisonswere
done between PTA0.5,1,2kHz thresholds with use of persons
homozygous for the 35delG mutation as the reference
group. Fisher’s exact test was performedwith con-2# 2
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tingency tables of appropriately dichotomized data at
the median (50th percentile [P50]), 25th percentile (P25),
or 5th percentile (P5) of the frequency distribution for
PTA0.5,1,2kHz of the reference group. Given the multiple
comparisons made, we focused on the most clearly sig-
niﬁcant test results.
The group of 35delG homozygotes was used as a ref-
erence, or “standard,” group, because that group is well
deﬁned and is present in most of the previously reported
studies of GJB2 mutations as the cause of HI. Threshold
data (PTA0.5,1,2kHz) for all groups with a speciﬁc biallelic
combination of mutations were screened for the presence
of progression by performing analysis of the linear regres-
sion of threshold on age (at audiometry, in years). If
there was no signiﬁcant correlation coefﬁcient ( )P ! .025
combined with a positive slope, it was concluded that
there was no signiﬁcant progression.
Results
Study Sample
The study sample consisted of 638 (41.7%) males and
607 (39.6%) females; sex information was not available
for 286 patients (18.7%). The median age of all par-
ticipants was 8 years; 90% of persons were within the
age range of 0–26 years (total age range, 0–70 years).
The majority of participants were white (90%), with
other subgroups fractionally represented—that is, Arabs
(4.8%), Ashkenazi Jews (2.4%), Asians (1.8%), Africans
(0.5%), and Roma Gypsies from the Czech Republic
(0.5%). Because the different ethnic subgroups were too
small for detection of a statistical difference between
groups, we used the sample set as a whole for statistical
evaluation. Linear regression analysis of thresholds on
age in the entire study sample and in subsamples deﬁned
by genotypes did not show signiﬁcant progression in any
samples; therefore, age was not used as a variable for
the analyses. This ﬁnding is in concordance with many
other studies (Denoyelle et al. 1999; Orzan et al. 1999;
Lofﬂer et al. 2001), although progression of hearing loss
cannot be deﬁnitively excluded, given the cross-sectional
nature of the regression analysis. A slight degree of asym-
metry was found in this study sample; however, the dif-
ference in PTA0.5,1,2kHz between the two ears was !15 dB
in 90% of the persons.
GJB2 Mutation Spectrum
A total of 83 different mutations were identiﬁed, which
were subclassiﬁed as 47 nontruncating and 36 truncat-
ing mutations (table 1). These mutations were associated
with 153 different genotypes, of which 56 were homo-
zygous truncating (T/T), 30 were homozygous nontrun-
cating (NT/NT), and 67 were compound heterozygous
truncating/nontruncating (T/NT). The nine most com-
mon mutations, including 35delG, had a frequency 11%.
Of the remaining 74 mutations with a frequency 11%,
27 had frequencies 10.1%; the remainder were very rare,
with frequencies !0.1%. It is possible that the two mu-
tations del(GJB6-D13S1830) and IVS11GrA were
underrepresented in this study. This might be because
many patients had been ascertained before del(GJB6-
D13S1830) was characterized (Lerer et al. 2001; del
Castillo et al. 2002); also, IVS11GrA lies outside the
GJB2 coding region and so was not included inmutation
screens by all laboratories.
The most prevalent mutations in population subgroups
were 35delG (65% of mutant alleles) in Arabs, 167delT
(84%) in the Jewish Ashkenazi population, and V37I
(37%) in Asians. Persons of African origin did not carry
a “common” mutation. Of the eight unrelated Roma
Gypsies, six were homozygous forW24X, onewas a com-
pound heterozygote for W24X/35delG, and one carried
the M34T/R127H combination. These ﬁndings are in ac-
cordance with the study reported byMinarik et al. (2003)
and Seeman et al. (2004), which showed that W24X is
a prevalent mutation in the Roma population.
Comparison of HI between Different Genotype Classes
By classifying variants as truncating or nontruncating,
we deﬁned three genotype classes: biallelic truncating (T/
T) (1,183 persons [77.3%]; 56 genotypes [37%]), bial-
lelic nontruncating (NT/NT) (95 persons [6.2%]; 30 ge-
notypes [20%]), and compound heterozygous truncat-
ing/nontruncating (T/NT) (253 persons [16.5%]; 67 ge-
notypes [44%]). The HI across classes is nonrandomly
distributed (x2 testing, ) (ﬁg. 1), with the HIP ! .0001
in the biallelic T/T class more severe than in the T/NT
class, which is more severe than in the NT/NT class.
Within the T/T and T/NT classes, we distinguished be-
tween 35delG and non-35delG mutations. This distinc-
tion had little impact on the distribution of HI, which
remained similar irrespective of the nature of the muta-
tion (35delG vs. non-35delG) (x2 testing: T/T class Pp
; T/NT class )..39 Pp .42
In the T/T class, 59%–64% of persons had profound
HI, 25%–28% had severe HI, 10%–12% had moderate
HI, and 0%–3% had mild HI. In the T/NT class, 24%–
30% of persons had profound HI, and 10%–17% had
severe HI, with a shift toward severe-to-profound de-
grees of HI in persons with two non-35delG mutations,
although this difference was not signiﬁcant (x2 testing,
). More than half (53%) of persons in the NT/Pp .42
NT class had only a mild degree of HI, and only one
person in ﬁve in this class had severe-to-profound HI.
Comparison of HI between Speciﬁc GJB2 Genotypes
To investigate hearing thresholds by genotype, we con-
structed scatter diagrams showing the binaural mean
PTA0.5,1,2kHz for each person within each genotype class
(ﬁg. 2). The reference group (35delG/35delG) is included
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Table 2
Genotypes of Study Subjects Whose Degree of HI Was Signiﬁcantly
Different from That of the Reference Group (35delG/35delG)
Mutation PTA0.5,1,2kHz P
a
Truncating/truncating (T/T):
35delG/631delGT 22 .0022
35delG/W77X 32 .0034
35delG/W172X 45 .0191
310del14/W24X 55 .0416
310del14/Q57X 49 .0247
W24X/IVS11GrA 53 .0337
Truncating/nontruncating (T/NT):
35delG/I20T 52 .0337
35delG/H100Y 47 .0213
35delG/M101T 32 .0034
35delG/S139N 29 .0022
35delG/A40E 50 .0045
35delG/G160S 16 .0011
31del38/L90P 53 .0337
167delT/V37I 50 .0281
167delT/L90P 45 .0191
235delC/V37I 29 .0022
310del14/V37I 30 .0034
310del14/L90P 25 .0045
Y65X/L90V 30 .0034
IVS11GrA/L90P 48 .0247
IVS11GrA/R184P 40 .0112
Nontruncating/nontruncating (NT/NT):
M34T/V95M 5 .0011
M34T/R143W 41 .0112
M34T/V153I 28 .0022
V37I/R143W 23 .0022
V37I/G160S 20 .0011
V37I/N206S 24 .0022
V63M/D159N 38 .0079
L90P/S139N 22 .0022
L90P/V153I 38 .0079
V95M/L90P 72 .0165
V153I/T8M 1 .0011
T123N/T123N 56 .0028
NOTE.—All genotypes were present in only one participant except
for the genotypes 35delG/I20T, 310del14/L90P, V95M/L90P, and
T123N/T123N (shown in bold italics), which were present in two
participants.
a P values were calculated by comparing the median PTA0.5,1,2kHz of
each genotype with the median PTA0.5,1,2kHz of the reference group, by
use of Fisher’s exact test.
Figure 2 Scatter diagrams of the PTA0.5,1,2kHz of groups with speciﬁc genotypes. The genotypes were divided into three classes, truncating/
truncating (A), truncating/nontruncating (B), and nontruncating/nontruncating (C). The genotypes are shown (left to right) in descending order
of group median PTA0.5,1,2kHz. The dividing lines used to dichotomize the threshold data in any group, as well as the reference group (“ref”),
are shown as horizontal lines at 100 dB (∼P50 of the reference group), 85 dB (∼P25), and 55 dB (∼P5). The P value indicated above the panel
frame relates to the Fisher’s exact test applying this dichotomy to both the reference group and the test group. HLphearing loss; “del(GJB6)”
represents the del(GJB6-D13S1830 mutation.
in each panel to facilitate visual comparisons, and bial-
lelic GJB2 genotypes are listed in descending order of
PTA0.5,1,2kHz. In ﬁgure 2, we have not included genotypes
that were present in only one or two persons. Instead,
these data are listed in table 2 and table 3. Table 2 contains
the genotypes of study subjects whose degree of HI was
signiﬁcantly different from that of the reference group,
and table 3, those that were not signiﬁcantly different.
The associated P value, for comparison of the PTA0.5,1,
2kHz with the reference group. is included in table 2 only.
These results must be interpreted with some caution be-
cause of small sample sizes.
Within the T/T genotype class shown in ﬁgure 2A,
only two genotypes differed signiﬁcantly from the ref-
erence group, persons segregating 35delG/del(GJB6-
D13S1830) had signiﬁcantly more HI (median
dB; ), whereas persons seg-PTA p 108 P ! .00010.5,1,2kHz
regating 35delG/IVS11GrA had signiﬁcantly less HI
(median dB; ). Among per-PTA p 64 P ! .00010.5,1,2kHz
sons with T/NT genotypes (ﬁg. 2B), one genotype,
35delG/R143W, showed signiﬁcantly more HI than did
the reference group, and eight genotypes had signiﬁ-
cantly less HI. The three genotypes with the least HI
were 35delG/V37I (median dB;PTA p 40 P !0.5,1,2kHz
), 35delG/M34T (median dB;.0001 PTA p 340.5,1,2kHz
), and del(GJB6-D13S1830)/M34T (medianP ! .0001
dB; ). In the T/NT geno-PTA p 25 P ! .00010.5,1,2kHz
type class, the threshold distribution in persons with
35delG/L90P suggests a bimodal distribution (ﬁg. 2B).
Seven 35delG/L90P compound heterozygotes had
dB, and 34 had dB,PTA 1 95 PTA ! 650.5,1,2kHz 0.5,1,2kHz
with the PTA0.5,1,2kHz of only one person falling between
the two values (65–95 dB). Among the NT/NT genotype
class, participants with three genotypes showed HI sig-
niﬁcantly different from that of the reference group:
M34T/M34T (median dB; ),PTA p 30 P ! .00010.5,1,2kHz
V37I/V37I (median dB; ),PTA p 27 P ! .00010.5,1,2kHz
and M34T/V37I (median dB;PTA p 23 P !0.5,1,2kHz
)..001
Figure 3 shows the P50, P10, and P90 of hearing
thresholds in audiogram format for genotypes with HI
signiﬁcantly different from that of the reference group.
We did not plot P10 and P90 values when . Ge-n ! 10
notypes represented by a small number of persons or a
large variation in threshold ( and dB) alson ! 5 SD 1 25
were excluded. It is noteworthy that the audiogram slope
of nearly all genotypes is fairly similar to that of the
35delG homozygote reference group (i.e., mildly down-
sloping), although the rather ﬂat conﬁguration seen with
the 35delG/IVS11GrA genotype is an exception.
The distribution of the degree of HI for the most prev-
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Table 3
Infrequent Study GJB2 Genotypes, with HI Not
Signiﬁcantly Different from That of the Reference
Group (35delG/35delG)
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
alent genotypes ( ) is given in table 4. Of 18n  10
genotypes, 10 (shown in bold italics) had an HI that
was signiﬁcantly different from that of the homozygous
35delG reference group.
Discussion
In this study of persons segregating GJB2-related deaf-
ness, we found truncating mutations of GJB2 to be as-
sociated with a greater degree of HI than were nontrun-
cating mutations. Several of the common genotypes in
this study group were associated with mild-to-moderate
HI, which suggests that completeGJB2mutation screen-
ing, including IVS11GrA and del(GJB6-D13S1830),
should be offered to all children with nonsyndromic HI,
regardless of severity.
The pathogenicity of missense mutations depends on
many factors, including the position of the mutation in
the protein and the nature of the substitution. For ex-
ample, a change in an amino acid that is positioned in
a functional domain or that is conserved in related genes
or species is likely to be pathogenic. However, given the
complex structure and function of gap junctions, it is
extremely difﬁcult to predict pathogenicity of somemis-
sense mutations. This limitation reﬂects our incomplete
understanding of the molecular basis for gap-junction
function, and it is for this reason that data from animal
models and recombinant expression systems, although
valuable for the investigation of mutations, should be
extrapolated to humans with caution.
Gap-junction channels are permeable not only to ions
but also to small metabolites with relative molecular
masses up to ∼1,200 Da (Harris and Bevans 2001), with
differences in ionic selectivity and gating mechanisms
among gap junctions that reﬂect the existence of 120
different connexin isoforms in humans. Of the handful
of GJB2 mutations that have been tested in recombi-
nant expression systems, most show a loss of function
due to altered sorting (G12V, S19T, 35delG, and L90P),
inability to induce formation of homotypic gap-junc-
tion channels (V37I, W77R, S113R, delE120, M163V,
R184P, and 235delC), or interference with translation
(R184P). Most GJB2 mutations, however, have not been
studied, and their impact on gap-junction function re-
mains speculative.
Of the reported functional studies, some results are
in apparent contradiction with our data. In particular,
the predicted gating properties of IVS11GrA, V37I,
and L90P are discrepant with the degree of HI we ob-
served. Expression studies have demonstrated complete
loss of channel activity for V37I and L90P (Bruzzone
et al. 2003; Skerrett et al. 2004), although we found
these mutations to be associated with mild-to-moderate
HI, and functional studies of 35delG and IVS11GrA
do not yield detectable CX26 protein and mRNA, re-
spectively (D’Andrea et al. 2002; Shahin et al. 2002),
which is inconsistent with our observation that 35delG/
IVS11GrA compound heterozygotes had signiﬁcantly
less-severe HI ( ) compared with 35delGP ! .0001
homozygotes. For the M34T allele variant, data are
even more contradictory. Some functional studies have
demonstrated a complete loss of channel activity for
this mutation, whereas other studies have shown that
this variant affects neither the permeability of dyes nor
the formation of stable connexons (Oshima et al. 2003;
Skerrett et al. 2004).
The difﬁculty in data interpretation is illustrated by
functional studies of V84L, which have shown no ap-
preciable effect on channel properties, although the mu-
tation has been proven to be clearly associated with HI
in humans (D’Andrea et al. 2002; Bruzzone et al. 2003).
A recent study by Beltramello and colleagues (2005),
which reviews the limitations of our knowledge of gap-
junction function, reports that the V84L mutant causes
HI due to an impaired permeability to IP3. The spread-
ing of an IP3-mediated Ca
2 signal is essential for the
propagation of Ca2 waves in cochlear supporting cells.
This discovery implicating IP3 as an essential component
for the perception of sound is very promising for future
studies of GJB2 mutations, especially when functional
studies and clinical data are discordant (i.e., for M34T
and V37I).
GJB6 is unique because of its chromosomal localiza-
tion within 50 kb of GJB2. A frequent mutation in-
cluded in this study, del(GJB6-D13S1830), leaves the
GJB2 coding region intact but deletes a large region
close to GJB2 and truncates GJB6. This deletion is fre-
quently found in compound heterozygosity with aGJB2
mutation, and the associated HI is assumed to be caused
either by the deletion of a putative GJB2 regulatory
element or by digenic inheritance (del Castillo et al.
2002). Pure digenic inheritance, however, seems un-
likely, since compound heterozygosity with a GJB2 mu-
tation has not been found for other GJB6 mutations.
We found del(GJB6-D13S1830) to be one of two muta-
tions associated with HI that is signiﬁcantly worse than
that of the homozygous 35delG reference group (the
other is 35delG/R143W). The 33 35delG/del(GJB6-
D13S1830) compound heterozygotes we ascertained
showed the highest median PTA0.5,1,2kHz (108 dB) in this
study. The regulatory-element hypothesis could explain
this ﬁnding, since deletion of this element would both
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Figure 3 Audiogram format for genotypes with an HI that was signiﬁcantly different from that of the reference group of 35delG
homozygotes. Only genotypes represented by a minimum of ﬁve persons and with an SD !25 dB are included. Median (P50) threshold (solid
line) and P10 and P90 thresholds (dashed lines) are shown only for . The reference group (“Ref”) is included and is shaded in gray.n 1 10
“del(GJB6)” represents the del(GJB6-D13S1830 mutation.
abolishGJB2 expression and inactivate oneGJB6 allele.
If GJB6 partially substitutes for GJB2 inner ear func-
tion, as has been suggested (Ahmad et al. 2003), this
substitution would then be less efﬁcient, thus leading to
more-severe HI.
The 35delG/L90P genotype was associated with a bi-
modal distribution of the binaural mean PTA0.5,1,2kHz
(ﬁg. 2B). Although, as a whole, those with this genotype
had signiﬁcantly less HI than did the reference group,
a small group of 35delG/L90P compound heterozygotes
had severe-to-profound HI. The generally mild charac-
ter of the L90P mutation was corroborated by six ad-
ditional compound heterozygous L90P combinations
that all had signiﬁcantly less HI than did the reference
group—that is, combinations involving S139N, V153I,
31del38, 167delT, IVS11GrA, and 310del14. Only
two genotypes involving L90P (i.e., L90P/R143Q and
L90P/delE120) failed to show a signiﬁcant difference
from the 35delG/35delG genotype.
The M34T variant was described ﬁrst as an autoso-
mal dominant mutation (Kelsell et al. 1997), consistent
with the study byWhite and colleagues (1998), in which
it was reported to have a dominant negative effect over
wild-type CX26 in Xenopus oocytes. These dominant
effects were later attributed to an artifact in the ex-
pression levels of mutant and wild-type RNA that was
not controlled in the exogenous system (Wilcox et al.
2000). Other reports list the M34T allele as an auto-
somal recessive mutation in the presence of other GJB2
mutations or in the homozygous condition (Wilcox et
al. 2000; Houseman et al. 2001; Kenneson et al. 2002;
Wu et al. 2002), whereas other studies have stated that
this variant is not pathogenic (Grifﬁth et al. 2000; Feld-
mann et al. 2004). If M34T is indeed a polymorphism,
persons with the 35delG/M34T genotype are carriers of
only one GJB2 mutation (35delG), and their HI must
be caused by other unidentiﬁed mutations in GJB2 or
by other genes. Because of the large phenotypic vari-
ability among genetic causes of HI, we would expect a
highly variable degree of HI in these persons, with a
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Table 4
Degree of HI for the Most-Prevalent Genotypes ( )n  10
MUTATION AND GENOTYPE
NO. OF
SUBJECTS
NO. (%) OF SUBJECTS, BY HI SEVERITY
Mild Moderate Severe Profound
Truncating/Truncating (T/T):
35delG/del(GJB6-D13S1830) 33 0 (0) 1 (3) 5 (15) 27 (82)
35delG/35delG 889 9 (1) 89 (10) 222 (25) 569 (64)
W24X/W24X 12 0 (0) 0 (0) 3 (25) 89 (75)
35delG/W24X 13 0 (0) 0 (0) 5 (38) 8 (62)
35delG/E47X 29 0 (0) 1 (3) 10 (34) 18 (63)
35delG/310del14 42 0 (0) 3 (7) 11 (26) 28 (67)
35delG/167delT 45 2 (4) 4 (9) 13 (29) 26 (58)
167delT/167delT 17 0 (0) 3 (18) 5 (29) 9 (53)
35delG/IVS11GrA 16 1 (6) 9 (56) 3 (19) 3 (19)
Truncating/nontruncating (T/NT):
35delG/R143W 10 0 (0) 0 (0) 0 (0) 10 (100)
35delG/W77R 11 0 (0) 3 (27) 2 (18) 6 (55)
35delG/R184P 15 0 (0) 5 (34) 5 (33) 5 (33)
35delG/delE120 11 1 (9) 4 (36) 3 (28) 3 (27)
35delG/L90P 42 20 (48) 14 (33) 1 (2) 7 (17)
35delG/V37I 20 11 (55) 9 (45) 0 (0) 0 (0)
35delG/M34T 38 26 (68) 11 (29) 1 (3) 0 (0)
Nontruncating/nontruncating (NT/NT):
M34T/M34T 16 13 (81) 1 (6) 2 (13) 0 (0)
V37I/V37I 18 10 (55) 7 (39) 1 (6) 0 (0)
NOTE.—Genotypes with HI that is signiﬁcantly different from that of the reference group (35delG/
35delG) are shown in bold italics.
range from mild to profound. However, all persons with
a 35delG/M34T genotype had mild-to-moderate HI,
with a median PTA0.5,1,2kHz of 34 dB. Persons homozy-
gous for M34T had an even lower median PTA0.5,1,2kHz
value (30 dB). M34T is reported to have a high fre-
quency in the general white population, comparable to
that of 35delG (Green et al. 1999; Roux et al. 2004).
The lower frequency of M34T, compared with 35delG,
in the patient sample of this study may reﬂect reduced
penetrance or possible ascertainment bias toward more-
severe HI, since persons with mild HI are less likely to
see an otorhinolaryngologist for audiologic or genetic
testing. Although some studies report that V37I is not
pathogenic (Kelley et al. 1998; Kudo et al. 2000; Hwa
et al. 2003; Wattanasirichaigoon et al. 2004), we docu-
mented an association with mild HI in 9 of 10 genotypic
combinations in our study sample. This result is con-
sistent with other studies of this allele (Abe et al. 2000;
Wilcox et al. 2000; Kenna et al. 2001; Lin et al. 2001;
Marlin et al. 2001).
In spite of the genotype-phenotype correlations we
observed, signiﬁcant phenotypic variability within geno-
types remains. This variability may reﬂect the effect of
modiﬁer genes and/or environmental factors that lead
to incomplete penetrance and variable expression (Na-
deau 2001). If modiﬁer genes are involved, their char-
acterization will be essential for reﬁning genotype-phe-
notype correlations and improving the accuracy of phe-
notype prediction.
Acknowledgments
This study was supported by grants from the University of
Antwerp, the Vlaams Fonds voorWetenschappelijkOnderzoek
and the Interuniversity Attraction Poles program P5/19 of the
Belgian Federal Science Policy (to G.V.C.), and the National
Institutes of Health (National Institute on Deafness and Other
Communication Disorders [NIDOCD] R01-DC02842) (to
R.J.H.S.). Additional grants are from the Internal Grant
Agency of the Ministry of Health of the Czech Republic (IGA
MH CR NM 7417-3), the Israel ministry of science and tech-
nology (to K.B.A.), the Turkish Academy of Sciences in the
framework of the young scientist award program (MT/TUBA-
GEBIP/2001-2-19), the Polish State Committee for Scientiﬁc
Research (3P05A15024), the Programa Ramo´n y Cajal ofMin-
isterio de Ciencia y Tecnologı´a (to I.d.C.), the Spanish Fondo
de Investigaciones Sanitarias (FIS G03/203 and FIS PI020807),
the G. Passe & R. Williams Foundation (to H.H.M.D), and
NIDOCD grant DC005248 (to M.A.K.). This study was ini-
tiated through the European Union GENDEAF study group.
Author afﬁliations.—Department of Medical Genetics, Uni-
versity of Antwerp (R.L.S., N.H., and G.V.C.), and Depart-
ment of Otorhinolaryngology, University Hospital of Ant-
werp (P.V.d.H.), Antwerp; Departments of Otorhinolaryngol-
ogy (P.L.M.H. and C.W.R.J.C.) and Human Genetics (L.H.H.),
Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands; Services de Biochimie et de Biologie Mole´culaire
(D.F.) and d’Oto-Rhino-Laryngologie et de Chirurgie Cervico-
Faciale (F.D.) and Unite´ de Ge´ne´tiqueMe´dicale (S.M.), Hoˆpital
d’Enfants Armand-Trousseau, AP-HP, Paris; Clinic of Diabe-
tology, Neonatology and Birth Defects (J.W.) and Department
Snoeckx et al.: GJB2 Genotype-Phenotype Correlation 955
of Forensic Medicine (R.P.), Medical University of Warsaw,
Institute of Physiology and Pathology of Hearing (J.W. and
M.M.-M.), and Departments of Audiology and Laryngology
(E.N.-S.) and Medical Genetics (J.B. and W.W.), Institute of
Mother and Child, Warsaw; International Center of Hearing
and Speech, Kajetany, Poland (A. Pollak); Department of Pe-
diatrics, Rare Disease Center, University of Padua (A.Murgia),
and Child Audiology, Otosurgery Unit, University Hospital
Padua (E.O.), Padua, Italy; Medical Genetics Unit, Department
of Medicine, Istituti Clinici di Perfezionamento (P.C.), and
Department of Otorhinolaryngology, Service of Audiology,
University of Milan, Policlinico Hospital, Instituto di Ricerca
e Cura a Carattere Scientiﬁco (U.A.), Milan; Departments
of Medical Genetics, Molecular and Clinical Pharmacology
(A.R.J.) and Hearing, Speech and Voice Disorders (D.N.-H.),
Innsbruck Medical University, Innsbruck; Department of Child
Neurology, DNA Laboratory, Charles University Prague (P.S.),
and Department of Otorhinolaryngology, University Hospital
Motol (O.B.), Prague; Departments of Otology and Laryn-
gology (M.A.K.) and Pathology (H.L.R.), Harvard Medical
School, and Department of Otolaryngology, Children’s Hos-
pital, (M.A.K. and A.F.) Boston; Division of Pediatric Molec-
ular Genetics, Ankara University School of Medicine, Ankara,
Turkey (M.T. and A.I.); Department of Pediatrics, University
of Melbourne (H.-H.M.D.), and Genetic Health Services Vic-
toria (D.d.S.), Murdoch Childrens Research Institute, Royal
Children’s Hospital, Melbourne; Regional Clinical Molecular
Genetics Laboratory, Camelia Botnar Labs, Great Ormond
Street National Health Service Trust (L.J.), Nufﬁeld Hearing
and Speech Center, Royal National Throat Nose and Ear Hos-
pital (D.L.), and Clinical and Molecular Genetics Unit, Insti-
tute of Child Health (M.B.-G.), London; Department of Hu-
man Genetics and Molecular Medicine, Sackler School of
Medicine, Tel Aviv University, Tel Aviv (K.B.A. and Z.B.); Un-
idad de Gene´tica Molecular, Hospital Ramo´n y Cajal, Madrid
(I.d.C. and F.M.); Institute of Anthropology and Human Ge-
netics (N.B.) and Department of Otolaryngology, University
of Tubingen (M.P.), Tubingen, Germany; Department of Oto-
laryngology, University of Debrecen, Hungary (I. Sziklai and
T.T.); Boys Town National Research Hospital, Omaha (P.M.K.
and E.S.C.); Centre de Ge´ne´tique Humaine, Institut de Path-
ologie et de Ge´ne´tique, Loverval, Belgium (L.V.M. and P.H.);
Laboratoire de Ge´ne´tique Mole´culaire (A.-F.R. and N.P.-R.)
and Service d’Oto-Rhino-Laryngologie (M.M.), Centre Hos-
pitalier Universitaire Montpellier, Montpellier, France; De-
partments of Clinical Genetics (T.L.) and Otorhinolaryngology
(H.L.), Oulu University Hospital, Oulu, Finland; Department
of Audiology, Bispebjerg Hospital, Copenhagen (A. Parving);
John F. Kennedy Institute, Glostrup, Denmark (K.G.); De-
partment of Pathology and Pediatrics, Stanford University
Medical Center, Stanford (I. Schrijver); California Ear Institute,
Palo Alto, San Ramon, and San Jose (J.R.); Dipartimento di
Medicina Sperimentale e Diagnostica, Sezione di Genetica
Medica (F.G.), and Cattedra di Audiologia (A. Martini), Uni-
versity of Ferrara, Ferrara, Italy; Service d’ORL, Hoˆpital
Edouard Herriot, Lyon, France (G.L.-G.); Center of Genetics
and Molecular Biology, University of Lisbon, Lisbon (C.C. and
G.F.); Johnson & Johnson Pharmaceutical Research and De-
velopment, Janssen Pharmaceutica, Beerse, Belgium (K.C.);
and Department of Otolaryngology and Interdepartmental
Ph.D. Program in Genetics, University of Iowa, Iowa City
(C.J.N. and R.J.H.S.).
Web Resources
The URLs for data presented herein are as follows:
Connexin-Deafness Home Page, http://davinci.crg.es/deafness/
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for GJB2)
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